MRI in High-Grade Glioma Patients Undergoing Chemoradiation
A Feasibility Study of Interim PET-MRI in High-grade Glioma Patients Undergoing Chemoradiation
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Pathologically confirmed diagnosis of high-grade glioma (grade III or IV) or WHO grade II glioma, IDH wildtype (molecular glioblastoma multiforme \[GBM\]). * ≥18 years of age. * ECOG performance status of 0 to 3 * Anticipated to receive 6 weeks of chemoradiation Exclusion Criteria: * Does not speak or read English * Unable to participate in cognitive testing due to aphasia or other severe cognitive impairment as determined by the PI, or Dr. Cummings or her designee. * Unable to give informed consent * Past medical history of any kind of dementia or diagnosed with mild cognitive impairment prior to diagnosis with their brain tumor * Unable to safely fast for 8 hours prior to bloodwork or 6 hours prior to PET scan * Currently taking cognition-enhancing medications including: * Donepezil * Memantine * Armodafinil * Methylphenidate * Pregnant or nursing mothers. * Patients taking blood thinners will be excluded from the optional Lumbar Puncture only, they are eligible for participation in the main study-provided they meet inclusion/exclusion criteria
About the study
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, optional lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
What is being tested
- PET-MRI Brain Scan (procedure)
- Blood draw (diagnostic test)
- Memory testing (behavioral)
- Optional lumbar puncture for cerebrospinal fluid collection (procedure)
Sponsor: Wake Forest University Health Sciences · Participants: 16 · Started: Sep 2, 2022
Contact the study team
- Principal Investigator · Phone: 336-716-5772
Official record on ClinicalTrials.gov — NCT05212272
Locations in the U.S.
| North Carolina | Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.